Prime Medicine to Present at Upcoming Investor Conferences
August 31 2023 - 8:00AM
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company
committed to delivering a new class of differentiated one-time
curative genetic therapies, today announced that Keith
Gottesdiener, M.D., President and Chief Executive Officer of Prime
Medicine, will present at two upcoming investor conferences.
- 2023 Wells Fargo Healthcare Conference:
Fireside chat on Thursday, September 7, 2023, at 11:00 a.m. ET in
Boston, MA.
- Morgan Stanley Global Healthcare Conference:
Fireside chat on Monday, September 11, 2023, at 11:20 a.m. ET in
New York, NY.
Live audio webcasts of the Wells Fargo and Morgan Stanley
fireside chats will be available under “Events & Presentations”
in the News & Events section of the Company’s website at
www.primemedicine.com. Replays of all webcasts will be available on
the Prime Medicine website for 30 days following the
presentation.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to
creating and delivering the next generation of gene editing
therapies to patients. The Company is leveraging its proprietary
Prime Editing platform, a versatile, precise and efficient gene
editing technology, to develop a new class of differentiated,
one-time, potentially curative genetic therapies. Designed to make
only the right edit at the right position within a gene while
minimizing unwanted DNA modifications, Prime Editors have the
potential to repair almost all types of genetic mutations and work
in many different tissues, organs and cell types.
Prime Medicine is currently progressing a diversified portfolio
of eighteen programs initially focused on genetic diseases with a
fast, direct path to treating patients or with a high unmet need
because they cannot be treated using other gene-editing approaches.
Over time, the Company intends to maximize Prime Editing’s
therapeutic potential and advance potentially curative therapeutic
options to patients for a broad spectrum of diseases. For more
information, please visit www.primemedicine.com.
Investor Contact
Hannah DeresiewiczStern Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media Contact
Dan Budwick, 1ABdan@1ABmedia.com
Prime Medicine (NASDAQ:PRME)
Historical Stock Chart
From Apr 2024 to May 2024
Prime Medicine (NASDAQ:PRME)
Historical Stock Chart
From May 2023 to May 2024